SCHEMBL865860

SCHEMBL865860

OCCC(C(F)(F)F)C(F)(F)F

nearest known ligand 0.36

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.36
THRB P10828 1/20 0.33
CETP P11597 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15726994 0.77 LMNA (0.33)
SCHEMBL27581274 0.74
SCHEMBL8668525 0.73 DPP4 (0.50) DPP4THRBCETP
SCHEMBL28498799 0.73 TSHR (0.48) THRB
SCHEMBL28498800 0.73 THRB (0.48) THRBCETP
SCHEMBL1148823 0.72 CETP (0.33) CETP
SCHEMBL2988228 0.71
SCHEMBL6940066 0.71
SCHEMBL14152436 0.71
SCHEMBL2988235 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030194378-A1 Novel aerosol formulation containing a polar fluorinated molecule ASTRAZENECA AB (SE) 2003-10-16 US claimed
EP-1303258-A1 NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE AstraZeneca AB (SE) 2003-04-23 EP claimed
WO-2002003958-A1 NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE ASTRAZENECA AB (SE) 2002-01-17 WO claimed
WO-2023174773-A1 PHOTOALIGNING MATERIALS Rolic Technologies AG (CH) 2023-09-21 WO disclosed
WO-2020236795-A2 TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF NOVARTIS AG (CH) 2020-11-26 WO disclosed
US-10838301-B2 Resist composition, method of forming resist pattern, fluorine-containing compound, and compound TOKYO OHKA KOGYO CO., LTD. (JP) 2020-11-17 US disclosed
CN-109983597-A Organic electroluminescent device 柯尼卡美能达株式会社 2019-07-05 CN disclosed
US-20190194365-A1 COMPOSITION, MODIFICATION METHOD AND SELECTIVE MODIFICATION METHOD OF BASE MATERIAL SURFACE, PATTERN-FORMING METHOD, AND POLYMER JSR CORPORATION (JP) 2019-06-27 US disclosed
US-10208031-B2 Photocrosslinkable materials comprising alicyclic group ROLIC AG (CH) 2019-02-19 US disclosed
CN-109315046-A The manufacturing method and organic electroluminescent device of organic electroluminescent device 柯尼卡美能达株式会社 2019-02-05 CN disclosed
US-20170362381-A1 THERMALLY STABLE ALIGNMENT MATERIALS ROLIC AG (CH) 2017-12-21 US disclosed
EP-1966119-A1 PHOTOCROSSLINKABLE MATERIALS Rolic AG (CH) 2008-09-10 EP disclosed
EP-1860094-A1 Photocrosslinkable materials Rolic AG (CH) 2007-11-28 EP disclosed
WO-2007098029-A1 METHODS FOR PREPARING SULFONAMIDE SUBSTITUTED ALCOHOLS AND INTERMEDIATES THEREOF WYETH (US) 2007-08-30 WO disclosed
WO-2007071091-A1 PHOTOCROSSLINKABLE MATERIALS ROLIC AG (CH) 2007-06-28 WO disclosed
EP-1801097-A1 Photocrosslinkable materials Rolic AG (CH) 2007-06-27 EP disclosed
EP-1303258-B1 NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE ASTRAZENECA AB (SE) 2006-10-11 EP disclosed
US-20030194378-A1 Novel aerosol formulation containing a polar fluorinated molecule ASTRAZENECA AB (SE) 2003-10-16 US disclosed
EP-1303258-A1 NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE AstraZeneca AB (SE) 2003-04-23 EP disclosed
WO-2002003958-A1 NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE ASTRAZENECA AB (SE) 2002-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10208031-B2 Photocrosslinkable materials comprising alicyclic group DDC, ALAD, DYNC1LI1 DPP4 871/4885THRB 4854/4885CETP 4221/4885
US-10838301-B2 Resist composition, method of forming resist pattern, fluorine-containing compound, and compound AFF1, RER1, AFF2 DPP4 4869/4885THRB 3699/4885CETP 4416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.